The nonpartisan scorekeeper’s new report reinforces longstanding concerns about the 340B drug discount program, including ...

Hospitals and major drugmakers are battling over the financial impact of a government pilot program that could shake up how medicines are steeply discounted for low-income and uninsured patients.

A bipartisan group of 163 lawmakers is urging the Department of Health and Human Services (HHS) to cancel an upcoming pilot ...

A bipartisan group of lawmakers has sent a letter to the Department of Health and Human Services, asking the agency to cancel ...

One of the world’s biggest drug makers is suing the country’s smallest state. The argument is over a federal drug discount program ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ongoing scrutiny and congressional, judicial, and industry pressures.

The American Hospital Association is calling on federal regulators to launch an antitrust investigation into its claims of drug manufacturers’ actions regarding 340B rebate models. In a letter sent to ...

For-profit drug manufacturers want to change how the 340B Drug Pricing Program works, but going from upfront savings to back-end rebates will kill nonprofit health providers.

Congress is considering a new bill that, in theory, would boost low-income patients’ - especially Latinos’ - access to ...

Commercial: Is the 340B Drug Pricing Program the Next 'Too Big to Fail'? WASHINGTON, Aug. 19, 2025 /PRNewswire/ -- ADAP Advocacy today, as part of its 340B Project, aired its latest commercial calling ...

HIV remains a persistent public health challenge in the United States. While infection rates have steadily declined over the past decade, access to proven prevention strategies—especially pre-exposure ...